Similar articles

• Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.

  Barry AL, Fuchs PC, Pfaller MA. Barry AL, et al. Eur J Clin Microbiol Infect Dis. 1991 Dec;10(12):1080-1. doi: 10.1007/BF01984936. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1839381 No abstract available.
• In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.

  Olsson-Liljequist B, Hoffman BM. Olsson-Liljequist B, et al. J Antimicrob Chemother. 1991 Feb;27 Suppl A:11-7. doi: 10.1093/jac/27.suppl_a.11. J Antimicrob Chemother. 1991. PMID: 1827097
• In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae.

  Bergeron MG, Bernier M, L'Ecuyer J. Bergeron MG, et al. Infection. 1992 May-Jun;20(3):164-7. doi: 10.1007/BF01704612. Infection. 1992. PMID: 1386590
• The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.

  Dabernat H, Delmas C, Seguy M, Fourtillan JB, Girault J, Lareng MB. Dabernat H, et al. J Antimicrob Chemother. 1991 Feb;27 Suppl A:19-30. doi: 10.1093/jac/27.suppl_a.19. J Antimicrob Chemother. 1991. PMID: 1827099
• Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

  Peters DH, Clissold SP. Peters DH, et al. Drugs. 1992 Jul;44(1):117-64. doi: 10.2165/00003495-199244010-00009. Drugs. 1992. PMID: 1379907 Review.